Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
CorneaGen
Seattle, Washington, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
CorneaGen commercially distributes donor corneal tissues and advanced ophthalmic surgical devices, including CTAK (a new therapy for keratoconus with immediate vision improvements), and has enabled tens of thousands of vision-restoring procedures annually[2][4]. Its spun-out cell therapy (Aurion Biotech) has shown Phase 2 and Phase 3 efficacy for corneal endothelial disease in Japan[1][3].
- Therapeutic areas
- Ophthalmology
- Modalities
- DeviceBiologic
- Industry
- Therapeutic Medical Devices
02
Partnerships
CTAK LLCZiemer (ophthalmic device company)[2]25+ U.S. eye/organ/tissue banks
Beyond the preview
Go deeper on CorneaGen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CorneaGen.